Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver

By Li Lu, Ying Li, S. Kim, W. Bossuyt, Pu Liu, Qiong Qiu, Yingdi Wang, G. Halder, M. Finegold, Ju-Seog Lee and 1 more. Proceedings of the National Academy of Sciences of the United States of America, 2010

748 citations recorded by the source corpus.

Subfields: Cell Biology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/57e6045cf8e826679f6292511b9a80bb70f222eb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. K. Guan
2. G. Halder
3. S. Piccolo
4. Fa-Xing Yu
5. Bin Zhao
6. Randy L. Johnson
7. Duojia Pan
8. M. Cordenonsi

In Molecular Biology

1. K. Guan
2. Bin Zhao
3. Duojia Pan
4. G. Halder
5. Fa-Xing Yu
6. Randy L. Johnson
7. S. Piccolo
8. Xaralabos Varelas

In Oncology

1. K. Guan
2. Bin Zhao
3. J. Shim
4. Duojia Pan
5. Randy L. Johnson
6. S. Piccolo
7. Robert F. Schwabe
8. G. Halder

Citations in the corpus

• YAP/TAZ at the roots of cancer (2016, background): “…Hippo pathway components causes some dramatic overgrowth phenotypes ultimately leading, at least in liver and intestine, to tumor development (Chen et al., 2015; Heallen et al., 2011; Lee et al., 2010; Lu et al., 2010; Song et al., 2010; Zhang et al., 2010; Zhou et al., 2009; Zhou et al., 2011a).”
• Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment (2013, background): “MST1/2 genes in hepatocytes resulted in enlarged livers (21, 22).”
• Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. (2012, background): “…cells Accumulating evidence supports an oncogenic role of YAP and a tumor suppressor function of the Hippo pathway (Overholtzer et al. 2006; Zender et al. 2006; Zhao et al. 2007; Steinhardt et al. 2008; Xu et al. 2009; Zhou et al. 2009; Lee et al. 2010; Lu et al. 2010; Pan 2010; Song et al. 2010).”
• Hippo signaling: growth control and beyond (2011, background): “…and Harvey, 2006; Brittle et al., 2010; Casal et al., 2006; Cho et al., 2006; Cho and Irvine, 2004; Ishikawa et al., 2008; Lawrence et al., 2007; Ma et al., 2003; Matakatsu and Blair, 2004; Matakatsu and Blair, 2006; Silva et al., 2006; Simon et al., 2010; Strutt and Strutt, 2002; Willecke et…”
• The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease (2014, background): “A similar onset of hepatocellular carcinoma is associated with liver-specific deletions of Sav1, Nf2 or both Mst1 and Mst2, all of which result in elevated nuclear YAP levels (Lee et al., 2010; Lu et al., 2010; Song et al., 2010; Zhang et al., 2010; Zhou et al., 2009).”
• Regulation of the Hippo-YAP pathway by G-protein coupled receptor signaling (2012, background): “Genetic ablation of Hippo pathway components in mice also leads to tumor formation (Benhamouche et al., 2010; Cai et al., 2010; Lee et al., 2010; Lu et al., 2010; Xu et al., 2009; Zhang et al., 2010; Zhou et al., 2009).”
• The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals (2010, background): “…Drosophila have implicated the apical membrane-associated FERM-domain proteinsMerlin (Mer) and Expanded (Ex) as pathway components upstream of Hpo (Maitra et al., 2006; Hamaratoglu et al., 2006; Pellock et al., 2007; Tyler and Baker, 2007), although how Mer and Ex regulate Hpo activity was not…”
• Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. (2012, methodology): “To test the feasibility of targeting the TEAD factors as a selective means of inhibiting YAP's oncogenic activity, we first used genetic approaches to inactivate the TEAD proteins in the mouse liver, an organ that is exquisitely sensitive to Hippo signaling (Camargo et al. 2007; Dong et al. 2007; Zh”
• The biology of YAP/TAZ: hippo signaling and beyond. (2014, methodology): “Moreover, oval cells were expanded after hepatotoxin injury in Sav mutants (127).”
• Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. (2015, neutral): “…regulators, usually results in expansion of progenitor cells, impaired cell differentiation, and hyperplasia of target tissues such as intestine, liver, skin, and nervous system (Cai et al., 2010; Camargo et al., 2007; Cao et al., 2008; Lee et al., 2008, 2010; Lu et al., 2010; Zhou et al., 2011).”